MAAT INDEX

CLAIM #11991 · Bristol-Myers Squibb Company (BMY) · 2024Q2 earnings call · Jul 26, 2024 · due Dec 31, 2026

Certainly, both trials have moved to the Part 2 of the study and you will continue to hear about how the trial progresses and we're looking forward to the readout starting in 2026.

Samit Hirawat · Chief Medical Officer

PENDING
graded after results covering Dec 31, 2026 are reported

How to check this claim

Look at: Public disclosure of Part 2 trial readout/data (topline or detailed results) for the two referenced studies

It came true if: At least one of the two trials reports readout data on or before 2026-12-31

Where: Company press release, clinical trial results disclosure (e.g., clinicaltrials.gov posting, medical conference presentation, or earnings call commentary)

Verify independently

SEC filings for BMY · Claim quote is verbatim from the 2024Q2 earnings call.